Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-18T03:17:28.145Z Has data issue: false hasContentIssue false

Assessment of the therapeutic impact of Allium sativum against the intestinal and intramuscular stages of murine trichinellosis

Published online by Cambridge University Press:  28 July 2025

S.K. Hammad
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Egypt
E.S. Elbahaie*
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Egypt
B.H. Abdel-Hameed
Affiliation:
Department of Medical Parasitology, Faculty of Medicine, Zagazig University, Egypt
*
Corresponding author: E.S. Elbahaie; Email: enas.elbahaie@gmail.com
Rights & Permissions [Opens in a new window]

Abstract

Trichinellosis is a global foodborne zoonotic disease. Numerous drugs used in its treatment exhibit inadequate absorption and diminished efficacy against encysted larvae in muscle tissue. Therefore, there is a need for innovative therapeutic agents to treat trichinellosis. Allium sativum (A. sativum), commonly known as garlic, is a bulbous plant that has been historically utilized in the treatment of various ailments. Currently, there is a paucity of data regarding the in vivo efficacy of A. sativum against trichinellosis. This study assessed the antiparasitic, anti-inflammatory, and antiapoptotic effects of A. sativum in murine models, independently or in conjunction with albendazole (ABZ), against the intestinal and muscular stages of trichinellosis. Fifty mice were equally categorized into five groups: negative control, positive control, ABZ, A. sativum, and a combination of ABZ and A. sativum. The effectiveness of the examined drugs was assessed through parasitological, biochemical, histological, and immunohistochemical methodologies. A. sativum resulted in a significant reduction of adult counts by 39.7% and larval counts by 54.4%. The inflammatory cellular infiltrate in the intestine and muscle was significantly reduced. In mice treated with A. sativum, serum levels of IFN-γ exhibited a significant increase, accompanied by a rise in Bcl-2 expression and a notable decrease in COX-2 expression. In conclusion, A. sativum demonstrates potential as a therapeutic agent for treating experimental trichinellosis, particularly during the muscle phase of the disease. It may serve as a safe promising therapy for trichinellosis.

Information

Type
Research Paper
Copyright
© The Author(s), 2025. Published by Cambridge University Press
Figure 0

Table 1.Mean adult T. spiralis count among the studied groups

Figure 1

Table 2.Serum IFN-γ levels on day 7 and day 40 pi

Figure 2

Figure 1.Histopathological examination of the small intestine of the studied groups (H&E). (a) Positive control group exhibited dense inflammatory infiltrate within villous cores (red arrows), villous tip sloughing (grey arrows), and villous broadening. (b) The positive control group demonstrated T. spiralis adult cross-sections embedded within architecturally distorted villi (red arrows). (c) The ABZ-treated group displayed mild to moderate lymphoplasmacytic infiltration in villous cores (red arrows). (d) The A. sativum-treated group showed a moderate inflammatory infiltrate (red arrows). (e) ABZ and A. sativum combination group revealed restored villous architecture with minimal inflammation (red arrows) (X200).

Figure 3

Figure 2.Histopathological examination of the diaphragm of the studied groups (H&E). (a) Positive control group with multiple T. spiralis larvae embedded in musculature (grey arrow) and dense inflammatory infiltrate (red arrows). (b) Higher magnification of positive control showing dense plasma-lymphocytic infiltrate within muscle bundles (red arrow). (c) The ABZ-treated group exhibited mild peri-larval inflammation (red arrow). (d) The A. sativum-treated group demonstrated a moderate peri-larval inflammatory infiltrate (red arrows). (e) ABZ and A. sativum combination group displayed markedly reduced plasma-lymphocytic infiltration (red arrow) (200X for a and 400X for b–e).

Figure 4

Figure 3.Immunohistochemical staining of Bcl-2 in the intestine of the studied groups. (a) The positive control group showed sparse, weak cytoplasmic Bcl-2 expression (red arrows) and epithelial ulceration (grey arrows). (b) The ABZ-treated group exhibited elevated Bcl-2 expression in the epithelial lining and interstitial inflammatory cells (red arrows). Regions devoid of expression exhibited a pale blue color (blue asterisk). (c)A. sativum treated group showed strong Bcl-2 expression (red arrows) and few non-reactive areas (blue asterisk). (d) The combination group of ABZ and A. sativum demonstrated a significant increase in Bcl-2 expression relative to the other groups (red arrows) (X400).

Figure 5

Figure 4.Immunohistochemical staining of COX-2 in the diaphragm of the studied groups. (a) Strong immunohistochemical expression of COX-2 was detected in positive control muscle sections (red arrows). (b) The ABZ-treated group exhibited decreased COX-2 expression in diaphragm myofibrils with a reduced intensity, which was demonstrated as a light brown color (red arrows). (c)A. sativum-treated group showed moderate expression of COX-2 in the inflammatory infiltrate surrounding T. spiralis larvae (red arrows). (d) The combination group of ABZ and A. sativum demonstrated minimal expression of COX-2 with reduced intensity of brown compared to the positive control (red arrows) (X400).

Figure 6

Figure 5.Bcl-2 and COX-2 immunoreactivity (area%).(a) Bcl-2 immunoreactivity in the intestinal sections on the seventh dpi.(b) COX-2 immunoreactivity in the diaphragm sections on the 40th dpi.** means p < 0.001 versus the positive control group